B+
Bull case
30%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
PLSE
Pulse BiosciencesFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The best post-print argument is that PLSE improved the pacing of its core AF program: management now expects NANOPULSE-AF enrollment completion in early Q4 2026, and the accompanying clinical update continued to show high procedural success and durability in feasibility patients [#PR-2026-05-04]. If execution holds, the stock can continue to trade on EP platform optionality rather than current revenue.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cash burn remains meaningful: Q1 2026 operating cash use was $14.6 million and quarter-end cash was $68.3 million, versus $80.7 million at year-end 2025 [#PR-2026-05-04].
Momentum
99
Value
37
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.00 · Bull $28.00 · Bear $13.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $50.80
Why
Momentum99 · Δ7d +0.0
Value37 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Cash burn remains meaningful: Q1 2026 operating cash use was $14.6 million and quarter-end cash was $68.3 million, versus $80.7 million at year-end 2025 [#PR-2026-05-04].
- • Clinical and regulatory risk is still central: AF and surgical AF programs require successful pivotal enrollment, follow-up, and eventual FDA clearance or approval, and the 10-K notes regulators can delay, limit, or deny authorization [#10-K-2026-02-19].
- • The quarter did not solve the core financial debate.
Catalyst clock
2026-06-30
ATM flexibility and indicated insider buying create a mixed near-term signal
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.3
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 99.1 / Value 36.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.34B
Beta
1.77
Shares Out
71.32M
P/E (TTM) · Derived
-43.3
P/S (TTM)
11504.73
P/FCF (TTM) · Derived
-51.97
Rev YoY
-100.0%
EPS YoY
+25.1%
Gross Margin
-43.2%
Op Margin
-7007.8%
Net Debt
-$73.21M
Current Ratio
9.63
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data